Visual Outcome Of A Case Of Maculopathy Following Implantation Of An Extended Macular Vision Intraocular Lens: A Case Report

To assess the change of best corrected visual visual acuity (BCVA) in a patient with mild cataract and maculopathy following bilateral phacoemulsification and implantation of EyeMax MONO IOL (Sharpview Ophthalmology, London, UK), an extended macular vision IOL designed to improve image quality across the macula up to 10o from the fovea.

Private practice, Trieste, Italy

We report the visual changes of A 76-year-old female patient with mild cortical cataract and maculopathy, which was more advanced in the right eye. The patient was hypertensive. Fundus examination showed atherosclerotic changes in retinal blood vessels, and macular dystrophic changes, more advanced in the right eye and drusen in the left eye. OCT showed suspected subretinal neovascular membrane in the right eye. She received several intravitreal injections of Ranibizumab (Lucentis) in the right eye, the last one was one month before the surgery. The intravitreal injection caused regression of the subretinal fluid. She underwent phacoemulsification and implantation of EyeMax Mono IOL in the left eye followed, one month later by the right eye. Both eyes were rendered hypermetropic postoperatively to ensure image magnification with spectacles. The refraction (sphere) in the right eye was +2.5D and, in the left, it was +1D. The baseline UCVA in the right and left eye were 0.4 decimal and 0.5 decimal, not correctable by spectacles. Three months following the surgery, BCVA in the right eye was between 0.5 and 0.6 decimal and fluctuating from 0.8 to 1 decimal in the left eye. At the last follow up, 3 years postoperatively, they were 0.6 and 0.8 decimal respectively. The left eye was treated with yag laser capsulotomy for posterior capsule opacification 2.5 years after the surgery. No other complication was detected.

The visual outcome of implantation of EyeMax Mono IOL for extended macular vision in both dry and stable wet macular degeneration showed that the IOL can safely improve visual acuity up to 3 years, in patients with center involving macular disease.